Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 6/20 | 0.39 |
| ▸ | HTR7 | P34969 | 6/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230681 | 0.90 | CACNA1B (0.43) | CACNA1BMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL5242024 | 0.90 | CACNA1B (0.42) | KDM4ECACNA1BMEN1KMT2AALDH1A1 | |
| SCHEMBL14431932 | 0.90 | L3MBTL1 (0.45) | KDM4ECACNA1BMEN1KMT2AALDH1A1 | |
| SCHEMBL5243213 | 0.90 | LMNA (0.50) | KDM4ECACNA1BMEN1KMT2AALDH1A1 | |
| SCHEMBL5235391 | 0.90 | CACNA1B (0.41) | CACNA1BMEN1KMT2AHTR1AHTR7 | |
| SCHEMBL5241749 | 0.89 | CACNA1B (0.48) | CACNA1BMEN1HTR1A | |
| SCHEMBL5240915 | 0.86 | KDM4E (0.42) | KDM4ECACNA1BPOLBGAAMEN1 | |
| SCHEMBL5241229 | 0.84 | CACNA1B (0.43) | CACNA1BMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL5240703 | 0.84 | ALDH1A1 (0.44) | CACNA1BMEN1KMT2AALDH1A1HTR1A | |
| SCHEMBL5752309 | 0.84 | CACNA1B (0.52) | KDM4ECACNA1BPOLBGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| EP-1818326-A1 | Nitrogen-containing heterocyclic compounds and pharmaceutical composition containing the compounds | Eisai R&D Management Co., Ltd. (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-04-20 | — | — | US | disclosed |
| US-6906072-B1 | Piperazine compound and pharmaceutical composition containing the compound | EISAI CO., LTD. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | EISAI CO., LTD. | 2004-11-04 | — | — | US | disclosed |
| EP-1254895-A1 | NITROGENOUS CYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220193-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1D, CACNA1B, CACNA1E | KDM4E 2814/4885CACNA1B 2/4885POLB 4044/4885 |
| US-20060084658-A1 | Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound | CACNA1B, CACNA1E, CACNA1D | KDM4E 3270/4885CACNA1B 1/4885POLB 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.